BPG is committed to discovery and dissemination of knowledge
Articles in Press
7/9/2024 6:55:39 AM | Browse: 34 | Download: 0
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 94379
Country China
Category Gastroenterology & Hepatology
Manuscript Type Editorial
Article Title Present and prospect of transarterial chemoembolization combined with tyrosine kinase inhibitor and PD-1 inhibitor for unresectable hepatocellular carcinoma
Manuscript Source Invited Manuscript
All Author List Rui Zhang, Yan-Hui Liu, Yu Li, Nan-Nan Li and Zheng Li
Funding Agency and Grant Number
Funding Agency Grant Number
The National Natural Science Foundation of China No. 82104525
The Natural Science Foundation of the Jiangsu Higher Education Institutions of China No. 21KJB360009
Corresponding Author Zheng Li, PhD, Pharmacist, Jiangsu Engineering Research Center of Cardiovascular Drugs Targeting Endothelial Cells, College of Health Sciences, School of Life Sciences, Jiangsu Normal University, No. 101 Shanghai Road, Xuzhou 221000, Jiangsu Province, China. lizhengcpu@163.com
Key Words Transarterial chemoembolization; Multi-targeted tyrosine kinase inhibitor; Programmed cell death protein-1 inhibitor; Unresectable hepatocellular carcinoma; Mechanism
Core Tip This editorial focuses on the mechanisms for combining transarterial chemoembolization with multi-targeted tyrosine kinase inhibitor and programmed cell death protein-1 inhibitor for unresectable hepatocellular carcinoma, administration sequence and selection of each medication, and implications for future clinical trials. Despite several retrospective trials have evaluated the efficacy and safety of this triple therapy, the flawed study design and heterogeneity in medications still arise controversial concerns on the results. Especially, the administration sequence between each medication varied across trials, which could greatly affect the clinical benefit. So, the administration sequence needs to be fully considered in future trials based on the interaction mechanisms between each medication.
Citation Zhang R, Liu YH, Li Y, Li NN, Li Z. Present and prospect of transarterial chemoembolization combined with tyrosine kinase inhibitor and PD-1 inhibitor for unresectable hepatocellular carcinoma. World J Gastrointest Oncol 2024; In press
Received
2024-03-18 14:22
Peer-Review Started
2024-03-18 14:22
To Make the First Decision
Return for Revision
2024-06-26 06:32
Revised
2024-07-01 13:44
Second Decision
2024-07-09 02:42
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2024-07-09 06:55
Articles in Press
2024-07-09 06:55
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https: //creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com